文献速递传染病防控与疫情报告免疫规划

葡萄糖吡喃糖脂佐剂增强小鼠埃博拉病毒样颗粒疫苗免疫应答

Glucopyranosyl lipid adjuvant enhances immune response to Ebola virus-like particle vaccine in mice.
PubMed 文献 · Vaccine · 2019-06-04

研究在小鼠模型中评估TLR4激动剂葡萄糖吡喃糖脂佐剂(GLA)稳定乳剂(SE)配制的埃博拉病毒样颗粒(VLP)疫苗的免疫原性与持久保护力。结果显示GLA-SE增强埃博拉特异性免疫,诱导Th1偏向抗体和多功能T细胞,并在末次接种后4周和22周致死性攻毒中提供长期保护。

要点

  • GLA-SE佐剂增强埃博拉VLP疫苗特异性抗体与T细胞应答。
  • GLA-SE诱导Th1偏向抗体及埃博拉GP特异性多功能T细胞。
  • 末次接种后4周和22周攻毒均显示长期保护。

核心结论

  • GLA-SE佐剂可增强埃博拉VLP疫苗免疫原性并诱导小鼠长期保护。

研究设计与样本

  • 小鼠模型研究,评估GLA-SE配制的埃博拉VLP疫苗免疫原性及攻毒保护。

主要发现

  • GLA-SE增强埃博拉特异性免疫并产生对小鼠适应埃博拉病毒的长期保护。
  • GLA-SE诱导Th1偏向抗体和埃博拉GP特异性多功能T细胞。

临床怎么用

  • 为TLR4激动剂GLA-SE作为蛋白疫苗佐剂的应用提供支持证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The identification of adjuvants that promote lasting antigen-specific immunity and augment vaccine efficacy are integral to the development of new protein-based vaccines. The Ebola virus-like particle (VLP) vaccine expressing Ebola virus glycoprotein (GP) and matrix protein (VP40) was used in this study to evaluate the ability of TLR4 agonist glucopyranosyl lipid adjuvant (GLA) formulated in a stable emulsion (SE) to enhance immunogenicity and promote durable protection against mouse-adapted Ebola virus (ma-EBOV). Antibody responses and Ebola-specific T cell responses were evaluated post vaccination. Survival analysis after lethal ma-EBOV challenge was performed 4 weeks and 22 weeks following final vaccination. GLA-SE enhanced EBOV-specific immunity and resulted in long-term protection against challenge with ma-EBOV infection in a mouse model. Specifically, GLA-SE elicited Th1-skewed antibodies and promoted the generation of EBOV GP-specific polyfunctional T cells. These results provide further support for the utility of TLR4 activating GLA-SE-adjuvanted vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sunay MME, Martins KAO, Steffens JT, et al. Glucopyranosyl lipid adjuvant enhances immune response to Ebola virus-like particle vaccine in mice. Vaccine. 2019. PMID: 31174937. doi:10.1016/j.vaccine.2019.05.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。